THE INTELLIGENCE BRIEFING OF THE INNOVATION ECONOMY
DAILY · SUNDAY · MONTHLY
OPENING ESSAY
The Questions You Carry Home
Capital can answer where the next piece of runway comes from. The work still has to answer what the uncertainty is asking of everyone who trusted the future enough to live inside it.
Across 77 distinct moves, the week followed capital from company financing and fund formation into debt, ownership transitions, operating handoffs, and the questions that remain after the announcement.
The capital record is public. The questions people carry home are not.
There are questions that do not stay at work. They come home with you because no amount of effort has convinced them to stay behind the screen: Where is the next check coming from? Can I cover the bills? Did I mistake conviction for a plan? Is the thing I am giving everything to still worth it?
Those questions change the temperature of a room. They sit underneath dinner, under the drive home, inside the quiet after everybody else has gone to sleep. Building a company is often described through its visible machinery: product, capital, customers, growth. The private machinery is harder to name. It is the strain of trying to build a future while wondering what the uncertainty is asking of the people who have trusted you enough to live inside it with you.
That is where the work stops feeling like an abstract professional risk. You look at the people beside you, fully committed to the life you are trying to make, and feel the weight of every unanswered question differently. The stakes have names, faces, groceries, school days, and bills with dates on them.
The usual language around grit is too clean for this. A person under that kind of pressure is not searching for a louder quote about hustle. They are trying to get through a difficult hour without letting fear make every decision for them. They are trying to keep the business moving while keeping the people they love from carrying the full force of what they do not yet know.
And still, people continue, with no new certainty and no improved relationship with anxiety. Some part of them understands that walking away in the middle of the hardest stretch would answer a question that time has not answered yet. The work gets smaller. Make the call. Send the note. Fix the problem. Look at the numbers. Go home. Wake up and find the next honest thing that needs to be done.
That is an unglamorous kind of belief. Belief without an audience, without a celebratory post, without any guarantee that the sacrifice will make sense in hindsight. A person doing what they can with what they have, while the rest of life keeps asking for proof.
Much of the innovation economy is carried through that invisible territory. Before a company has traction, before a founder has a story that sounds inevitable, there are people pushing through the parts no one gets to applaud. They do not always know why they keep going. They just know the next piece of work is still there, and the people they love deserve someone who will meet it with both hands.
Here's to Chris McGill and Jose Avila (Burlingame Studios); Todd Cushman (Bioness Medical); Nikolaj Hendriksen and Mark Rosenvinge (Hi Rasmus); Shishir Bankapur (Helogen); Omri Casspi and Ori Striechman (Swish Ventures); and Zain Asgar, Michelle Nguyen, Omid Azizi, Natalie Serrino, and James Bartlett (Gimlet Labs). Keep pushing forward.
Capital Answers One Question. The Work Brings the Rest Home.
The questions people carry home are not all solved by capital. Some are postponed. Others become larger. Across 77 distinct moves, the week showed money formalizing relationships, enlarging opportunities, transferring ownership, and preserving another attempt.
Forty-six exact current company financings totaled $2.524855B. A separate mixed package gave Félix Pago $87M of equity and $113M of credit. Keeping that structure outside the exact-company-financing subtotal preserves the difference between ownership capital and borrowing capacity.
Four fund-capital records totaled $12.01888B. Cherubic Ventures, CVC Secondary Partners, StepStone Group, and Swish Ventures did not announce company proceeds or capital already deployed. They created allocation mandates whose evidence will arrive through the companies chosen, ownership taken, liquidity provided, and support delivered after the check.
Six standalone debt, credit, and user-acquisition structures carried $554M of disclosed face value or capacity. JetZero, Scan.com, Odyssey Energy Solutions, Playfly Sports, Burlingame Studios, and Bioness Medical received instruments with different funding conditions and repayment obligations. The total does not imply that every dollar was drawn at announcement.
Six acquisitions entered the record. Descartes paid $100M for Tai Software. Lilly agreed to pay up to $2.875B for Merida Biosciences, with the upfront amount undisclosed and part of the maximum still tied to milestones. Four other acquisitions carried undisclosed terms. Ownership changed or was set to change; integration, retained trust, and operating performance will decide what the combinations became.
The record also kept unlike capital in its own lanes: Carrick's approximately $600M continuation vehicle beside Saviynt's separate $255M financing; Be Clinical's ₹21 crore Seed extension in its original currency; seven current investments with amounts undisclosed; two qualified financings totaling more than $179M; and three reported transactions still in progress.
The accounting matters because every lane changes the questions people carry. Equity asks a company to turn ownership into execution. Debt has to remain synchronized with assets and cash flow. Fund capital creates responsibility for selection. An acquisition moves the burden of proof to a new owner. The check can answer where the next piece of runway comes from. It cannot answer whether the company can make the work worth what people are carrying for it.
Seventy-seven moves carried capital into companies, funds, lenders, and acquisitions. None of the announcements removed the obligation to make the next day work.
Harvey keeps converting capital into enterprise adoption
GE Aerospace deployed Harvey across its Legal & Compliance organization after a pilot and is serving as a design partner for Contract Intelligence. Macpherson Kelley also announced a firmwide rollout on September 2.
These are customer-adoption records, not new financings. They show a company previously carried by WTMM becoming a name institutions call when legal work, contracts, and professional judgment have to move together.
Base Power moves from homes into Texas businesses
Base Power launched fixed-rate commercial electricity plans for businesses across ERCOT after piloting with commercial accounts. The company says early members saved an average of 20% on their energy rate.
The figure is company-reported, and the launch is not a capital event. It is a follow-through signal: a company already known for distributed residential batteries is asking whether the operating model can carry a second customer class.
Candid Health moves into oncology through Flatiron
Candid Health and Flatiron Health announced a partnership that will bring Candid's revenue-cycle platform to oncology practices across Flatiron's network. The work now moves into one of healthcare's more complicated billing environments, where treatment regimens, authorizations, claims, and collections have to stay connected.
WTMM first carried Candid Health with its $120M Series D. This partnership is what comes after the announcement: a previously funded company earning a path into a specialized operating system. It adds no new capital record.
Easy Aerial's operating record gets more complicated
Easy Aerial's recently reported $20M Series B now sits beside competing accounts about the nonrenewal of its Brooklyn Navy Yard lease. The company says political pressure followed an August 2025 demonstration; Navy Yard officials dispute that account and point to lease and space considerations.
The financing remains a financing. The lease dispute is separate evidence about operating environment, institutional relationships, and the costs a defense company may carry after the check.
Venture Week reaches Chicago
Venture Week's Chicago calendar runs September 6–12 as a decentralized collection of events for founders, investors, executives, operators, researchers, and others working across the innovation economy.
The week is an access signal, not a capital event. Its value will come from the specific rooms, people, and operating conversations it brings together—and from whether those connections continue after the calendar moves to the next city.
Source-verified ecosystem signals. These items are not funding records or capital events and are excluded from every capital count and total.
SYSTEM VIEW
WHAT THE WEEK ASKED THE WORK TO CARRY
Each of the 77 records appears once through its published Daily classification.CHOOSE
Decide who carries responsibility and where authority sits.BUILD
Create the physical, technical, clinical, and manufacturing foundation.EARN
Earn customer trust, category relevance, and the right for a name to travel.CARRY
Make partnerships, acquisitions, care pathways, and capital structures survive the handoff.GOVERN
Keep identity, security, data, ownership, and accountability intact.PROVE
Turn a larger opportunity into clinical, field, commercial, and infrastructure evidence.Editorial grouping of published Daily classifications, not a score or causal model.
NUMBERS THAT MATTER
CAPITAL BEHIND TODAY'S MOVES
Burlingame Studios
A player can finish a garden in 10 minutes. The revenue curve attached to that session may take months to finish telling the truth.
That gap is where mobile gaming starts behaving like working capital. The studio pays an acquisition channel for attention now. The cohort returns its answer through retention, in-app purchases, and payback later.
Gamigion reports that Burlingame Studios has secured $12M in user-acquisition financing from PvX Partners, primarily to scale Flourish by Garden Joy, the newly renamed version of Garden Joy. Exact pricing, maturity, covenants, and draw terms were not disclosed in the public reporting.
PvX describes its model as non-dilutive capital underwritten against cohort performance. The structure gives studios a way to finance marketing without selling another piece of the company every time a live game finds room to grow.
Chris McGill, co-founder and CEO, and Jose Avila, co-founder and CTO, are not learning casual games from a slide deck. Burlingame's founding team came through CrowdStar and Glu Mobile, with experience around Design Home and Covet Fashion before building a studio aimed at people who may not even describe themselves as gamers.
Flourish fits that thesis. It turns gardens, patios, furniture, plants, and daily design challenges into a live creative loop. Google Play shows more than 1M downloads, roughly 45K reviews, and a 4.7 rating. The game also features Better Homes & Gardens-branded challenges.
Scopely invested $20M in Burlingame Studios in March 2022. That earlier investment and this $12M facility belong in the same company history, but they should not be added together as if the capital works the same way. One helped launch a studio. The other is being pointed at the expensive interval between finding a player and collecting the revenue that player may eventually produce.
User acquisition is often discussed like a marketing tactic, but at live-game scale it becomes a financing decision. A promising cohort can be profitable on paper while the studio still lacks enough cash to keep buying the next one.
For operators, that makes growth a cash-management problem.
PvX is betting its underwriting can read that timing well enough to fund the gap. Burlingame Studios is betting Flourish can absorb more distribution without losing the economics that made the facility possible.
The garden may be designed one challenge at a time. The business now has $12M riding on whether the next cohort keeps growing after the first ad bill is already paid.
Deeper Analysis 👇 https://devcuration.com/articles/burlingame-studios-secures-12m-for-ua-growth
Bioness Medical
A patient does not recover inside one product category. The clinic still has to connect muscle activation, gait training, balance work, evidence, reimbursement, and a device the patient can actually use at home.
That is the operating reality behind Bioness Medical's new $15M senior credit facility from Horizon Technology Finance. Horizon funded $10M at closing and left up to $5M available for future growth. This is credit capacity rather than a $15M equity round, and the distinction matters.
Bioness has spent more than 20 years in neurorehabilitation. Its portfolio spans functional electrical stimulation, robotic gait support, interactive therapy, and, after an April acquisition, the PoNS neuromodulation system.
Accelmed acquired the business from Bioventus at the end of 2024 and re-established Bioness as an independent company. Since then, each product has brought more work around clearance, clinical integration, training, payer access, and patient adoption.
FDA records show a May 13 PoNS clearance for chronic stroke-related gait deficits when the prescription device is used alongside supervised therapeutic exercise in adults 22 and older. The clearance opens one door while Bioness still builds the evidence, reimbursement, clinician confidence, and commercial system that can get a patient through it.
Todd Cushman, co-founder and CEO, says the facility adds flexibility for innovation, portfolio expansion, and global service. Horizon's CIO Paul Seitz points to Bioness's proven model and market position. That is lender language, but the transaction puts senior capital behind a commercial medical-device business.
$10M is funded, and another $5M is available. Interest rate, maturity, covenants, warrants, and draw conditions were not disclosed. That leaves an incomplete capital picture, exactly the detail operators should keep straight when debt gets dressed like a funding round.
The strongest use of this money may be less photogenic than another product reveal. Bioness has to make several rehabilitation modalities work as one clinical and commercial story without letting portfolio breadth outrun evidence or access. The hard handoffs run from regulator to clinic, clinic to payer, therapist to patient, and device to daily life.
In neurorehabilitation, value appears when technology survives every handoff between the company and the person trying to move again. Bioness has $10M more to carry that work today, with another $5M waiting behind terms it has not disclosed.
Deeper Analysis 👇 https://devcuration.com/articles/bioness-medical-receives-15m-credit-facility
Hi Rasmus
The clinical record inside an autism-care session has to satisfy two audiences at once. It must help the clinician understand the child in front of them, then survive the supervisor, payer, and audit process that arrives later.
Hi Rasmus built its business inside that tension. Founder and CEO Nikolaj Hendriksen started the company after navigating autism care for his son, Rasmus. The platform brings data collection, treatment planning, documentation, scheduling, outcomes reporting, and AI-supported tools into one ABA-first clinical system.
Updata Partners VIII has invested $50M through a strategic minority investment. Hi Rasmus says it reached this point without outside capital while growing to serve more than 1,000 organizations across all 50 U.S. states and 90 countries. It also reports supporting more than 19.6M hours of client sessions annually and onboarding two of the world's largest ABA providers.
Updata General Partner Braden Snyder will join the board. The firm describes a rapidly growing, profitable company with strong retention and unit economics, although the supporting financial detail was not disclosed.
Hi Rasmus plans to invest in product, AI, enterprise capabilities, integrations, outcomes research, infrastructure, and go-to-market scale. CTO Mark Rosenvinge and the product organization now have more room to connect work usually split across clinical systems and billing-first software.
CMS released an ABA oversight toolkit in August after reporting that program spending rose much faster than the number of children receiving services from 2021 through 2025. That scrutiny does not belong to Hi Rasmus. The operating demand behind it does: individualized care, credible documentation, and evidence that the system produces the outcomes it claims.
Taking a minority investment after bootstrapping puts a growth investor on the board while founders retain majority ownership. Hi Rasmus gets capacity without handing away the product mission.
The next stretch will be decided inside ordinary sessions. If clinicians can collect cleaner data, finish documentation with less friction, and give supervisors a clearer view of outcomes, the platform can scale because care teams get time back. If the software becomes another administrative layer, $50M only buys a larger version of the same problem.
Hi Rasmus now has the capital to make clinical work and institutional proof meet in the same record. That handoff will keep happening one child, one clinician, and one session at a time.
Deeper Analysis 👇 https://devcuration.com/articles/hi-rasmus-50m-updata-partners-autism-care
Helogen
A surgeon will never buy microgravity. A surgeon will buy a material that arrives with evidence, sterility, traceability, and a reason to trust what happens after it enters the body.
That gap is where Helogen is placing a factory.
The New York and Los Angeles company has raised a reported $7.1M Seed round co-led by RRE Ventures and Oceans, with One Way Ventures and Blisce participating. Helogen's own disclosure puts total funding at $7.9M. AUM, Aurelia Foundry, Mana VC, and angels appear in the broader investor base.
Founder and CEO Shishir Bankapur started the business in 2022 as Odyssey SpaceWorks. Helogen is now narrowing the idea of autonomous laboratories in orbit into a harder commercial job: manufacturing biomaterials that can return to Earth and enter regulated products.
HEL-IOS combines cultivation, fluid management, processing, harvest, imaging, and sequencing in a zero-crew orbital factory. Helogen wants to own enough of the process to explain what happened to the material from launch through recovery.
October brings the next proof. One mission is planned to produce Helogen's biopolymers for orthopedic scaffolds used in knee and shoulder repair. Another will manufacture protein material for LambdaVision's artificial retina, taking that partner beyond the International Space Station for the first time.
The science is interesting. The handoffs decide whether it becomes a business.
Microgravity may allow biological structures to form differently. A regulator still needs bioburden controls, process consistency, material recovery, and chain of custody. A customer still needs a dependable product. Orbit makes those obligations more expensive to inspect.
Helogen says these flights begin work toward GMP-oriented production and future FDA oversight. That is a path, not an approval. It has outlined 8 missions over the following year, mixing proprietary products with customer-funded research.
RRE Ventures General Partner and COO Will Porteous called Helogen's vision the most complete approach to scaling biomanufacturing in space that his firm has seen. The company is trying to own the industrial loop, from biology and hardware to spacecraft and orbital infrastructure.
Now the loop has to close on Earth. Each flight must return more than an impressive mission patch. It must return usable material, better process knowledge, a cleaner regulatory record, and enough customer confidence to book the next factory run.
Deeper Analysis 👇 https://devcuration.com/articles/helogen-raises-71m-for-orbital-biomanufacturing
Swish Ventures
Twelve companies. Roughly $20M apiece. Swish Ventures just made concentration expensive.
Swish Ventures completed a $250M raise for Swish III, its new Seed and Series A fund. The vehicle lifts reported AUM to about $800M. Sequoia Capital, U.S. pension funds, endowments, and other institutional and family-office backers supported it.
That headline is large. The portfolio plan is deliberately small.
Omri Casspi and Ori Striechman expect to invest in roughly 12 companies across cybersecurity, AI and advanced infrastructure, Physical AI, defense, industrial AI, and technology for governments. At an average of about $20M per company, every yes carries weight.
Concentration is easy to admire from a distance. Up close, it means fewer places to hide a weak decision and more time owed to every founder at the table. The capital has to show up in recruiting, customers, later rounds, and the quiet weeks after the announcement.
Swish has earned the right to make the wager bigger. Forbes reports 20 portfolio companies, with eight now valued above $1B. Cognition, Eon, Upwind, and Applied Compute sit inside the same AI, cloud, and security demand that shaped the firm's early thesis.
Those marks are evidence of access and selection, not realized returns. The reported $800M AUM should not be confused with the $250M raised for this vehicle. Private valuations move, and distributions are different from headlines.
The architecture around Swish III reaches beyond one fund. Casspi began with the $36M Sheva vehicle in 2022, launched a $63M Swish fund in 2024, and added a $100M Opportunity Fund in late 2025. Swish can now enter earlier and keep supporting selected companies as they grow.
That can be powerful for founders who want a partner with room to stay involved. It also makes the selection funnel brutally narrow. A 12-company plan is a promise that attention will compound alongside ownership, not disappear into a portfolio dashboard.
Institutional LPs are backing that promise. Sequoia is the only investor named publicly, while the pension funds, endowments, and family offices remain undisclosed. Their bet is that Casspi's founder access and competitive judgment can become an institution without turning into an assembly line.
The next proof will live inside the work around those 12 companies: which founders get chosen, how much ownership Swish earns, and whether a larger pool still leaves room for the calls and decisions that made concentration valuable in the first place.
Deeper Analysis 👇 https://devcuration.com/articles/swish-ventures-closes-250m-fund-iii
Gimlet Labs
One inference request can look simple from the application layer. Underneath it, an infrastructure team is deciding which chip handles each phase and whether power, memory, cooling, and latency can keep the agent useful.
Gimlet Labs is raising infrastructure-scale money to make that machinery disappear from the developer's view.
The San Francisco company announced a $300M Series B led by Andreessen Horowitz at a $3B valuation, bringing total funding to $392M. Sapphire Ventures, Menlo Ventures, Arm, M12, Eclipse, Factory, Tiger Global, and a broad group of new and returning investors joined the round.
Gimlet emerged from stealth in October 2025 with a $12M Seed, then raised an $80M Series A in March. 5 months later, the question is how quickly it can operate heterogeneous inference at datacenter scale.
Zain Asgar, Co-Founder and CEO, built Gimlet with Michelle Nguyen, Omid Azizi, Natalie Serrino, and James Bartlett. The team previously built distributed systems at Pixie Labs before New Relic acquired it.
Gimlet breaks an AI workload into pieces and maps each to the hardware that fits it best. GPUs can keep compute-heavy work while memory-bound phases move elsewhere. A compiler, runtime, and orchestration layer keep the mixed fleet behaving like one system.
The pitch sounds elegant because the operational problem is not. Mixed systems bring different performance profiles, networking demands, rack densities, power needs, and cooling requirements. Sometimes the advantage lives in a compiler. Sometimes it is sitting in a pipe, waiting for an engineer.
Gimlet says it has added billions in contracted revenue since March, built a gigawatt-scale pipeline, and is scaling toward hundreds of megawatts of managed capacity. It also reports 5-10X speedups for the same power footprint. Those are company-reported figures, not independent benchmarks.
The capital will expand Gimlet's team and cloud operations. Andreessen Horowitz is backing a shift in where AI infrastructure value may collect: making a mixed fleet feel boring enough for a developer to trust.
Performance can win the demo. The business is built when the system keeps choosing the right hardware across changing workloads and physical constraints without handing the complexity back to the customer. Gimlet now has the money to carry that promise into facilities where software decisions meet megawatts, cooling loops, and contracts.
Deeper Analysis 👇 https://devcuration.com/articles/gimlet-labs-raises-300m-series-b-at-3b-valuation
THE CLOSING SIGNAL
The capital record is public. The questions people carry home are not.
Across 77 moves, capital formalized partnerships, transferred ownership, created allocation mandates, and kept unfinished work alive. The next record will be written through customer trust, operating discipline, clinical evidence, physical output, and the people who return to the work while the hardest questions are still waiting for answers.
FREE PUBLICATION · EVERY EDITION
Every issue. Delivered when it publishes.
WTMM is currently free. Subscribe once and receive every Daily, Sunday, Monthly, and future edition automatically.NO CARD REQUIRED